Piper Sandler Maintains Neutral on Guardant Health, Lowers Price Target to $35
Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Neutral and lowers the price target from $50 to $35.
JP Morgan Maintains Overweight on Guardant Health, Lowers Price Target to $65
JP Morgan analyst Julia Qin maintains Guardant Health (NASDAQ:GH) with a Overweight and lowers the price target from $75 to $65.
Credit Suisse Maintains Outperform on Guardant Health, Lowers Price Target to $60
Credit Suisse analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and lowers the price target from $70 to $60.
Guardant Health Q4 EPS $(1.17) Beats $(1.37) Estimate, Sales $126.89M Beat $124.08M Estimate
Guardant Health (NASDAQ:GH) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.37) by 14.6 percent. This is a 69.57 percent decrease over losses of $(0.69) per share from the
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Magistrate Judge Issued Favorable Recommendation Regarding Guardant Health’s Motion To Dismiss Lawsuit Brought By Illumina
Guardant Health, Inc. (Nasdaq: GH) issued the following statement today regarding the favorable recommendation by U.S. District Court Magistrate Judge Christopher J. Burke that nearly all claims brought by Illumina against Guardant Health in a lawsuit filed on March 17, 2022, be dismissed:
Guardant Health To Showcase New Data At ASCO GI 2023 Demonstrating Utility Of Its Blood Tests For Patients With Gastrointestinal Cancers
Presentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers and predict disease recurrence and response to therapy
Cathie Wood Makes This Molecular Diagnostics Company Top Holding Of Ark Invest’s Flagship Fund, Catapulting Past Zoom, Tesla
Shares of Exact Sciences, Inc. (NASDAQ: EXAS) have been on a tear, having gained over 27% in two sessions this week.
Scotiabank Initiates Coverage On Guardant Health with Sector Outperform Rating, Announces Price Target of $36
Scotiabank analyst Sung Ji Nam initiates coverage on Guardant Health (NASDAQ:GH) with a Sector Outperform rating and announces Price Target of $36.